MedRx Co., Ltd (TYO: 4586)

Market Cap	3.88B
Revenue (ttm)	255.00M
Net Income (ttm)	-581.00M
Shares Out	47.35M
EPS (ttm)	-14.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	340,800
Open	79.00
Previous Close	80.00
Day's Range	79.00 - 83.00
52-Week Range	76.00 - 199.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 7, 2025

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 22
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4586

Financial Performance

In 2023, MedRx's revenue was 29.00 million, a decrease of -50.85% compared to the previous year's 59.00 million. Losses were -932.00 million, -16.11% less than in 2022.